Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine (Nasdaq: CMND) announced completion of patient enrollment for the second cohort in its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Dec. 16, 2025. The six-patient cohort was recruited rapidly across three clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

The trial is multinational and will assess safety, tolerability, pharmacokinetics, and preliminary efficacy in moderate-to-severe AUD. Dosing for the second cohort is expected to start shortly, and topline results are anticipated in the coming months. The announcement references encouraging topline safety and preliminary efficacy signals from the first cohort.

Clearmind Medicine (Nasdaq: CMND) announced a peer-reviewed review published Dec 2, 2025 in Current Addiction Reports evaluating its proprietary candidate MEAI (CMND-100) for alcohol use disorder (AUD).

The review, led by experts including Anahita Bassir Nia from Yale, examines MEAI's pharmacology, receptor interactions, preclinical efficacy, and emerging clinical observations, and positions MEAI as a potential AUD treatment with milder subjective effects and lower cardiovascular, neurotoxicity, and abuse potential than MDMA and classic psychedelics. Recreational dosing reported at 1–2 mg/kg orally with positive effects around 4 hours is cited. The review notes no serious adverse events reported by recreational users but highlights there are no published human adverse‑effect studies to date, while receptor data suggest reduced 5-HT2A/2B/2C activity and no 5-HT2B calcium flux agonism.

Clearmind Medicine (Nasdaq: CMND) announced on Dec 12, 2025 that Nasdaq notified the company on Dec 10, 2025 it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Stockholders' Equity Rule requiring at least $2,500,000 in stockholders' equity. The notice follows Clearmind's Form 6-K filed Dec 5, 2025. Nasdaq said it will continue to monitor the company's compliance and warned that if Clearmind does not demonstrate compliance at its next periodic report, it may be subject to delisting. The company remains a clinical-stage biotech developing neuroplastogen-derived therapeutics.

Clearmind Medicine (Nasdaq: CMND) will implement a 1-for-40 reverse share split effective December 15, 2025 to regain compliance with the Nasdaq Minimum Bid Price Rule. The board approved the reverse split on November 12, 2025. The reverse split will reduce the number of issued and outstanding common shares from 59,991,852 to 1,499,796, subject to fractional-share treatment.

No fractional common shares will be issued; instead, fractional shares will be rounded up to the nearest whole share. The company said authorized share capital remains unchanged and that outstanding options and warrants will be proportionately adjusted in quantity and per-share exercise price.

Clearmind Medicine (Nasdaq: CMND) received a Nasdaq notice on December 4, 2025, for noncompliance with the $1.00 minimum bid price requirement after the closing bid was below $1.00 for 30 consecutive business days.

Nasdaq granted a 180-calendar day compliance period through June 2, 2026 to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. The companyshares will continue to be listed and traded under the symbol CMND during the period. If not compliant by June 2, 2026, the company may seek a second 180-day period only if it meets market value and other initial listing standards (except the bid-price rule). The company said it will monitor the closing bid and consider options to cure the deficiency, but provided no assurance it will regain compliance.

Clearmind Medicine (Nasdaq: CMND) announced the first participant was enrolled and dosed with CMND-100 at Hadassah-University Medical Center in Jerusalem on Dec. 2, 2025 as part of its multinational Phase I/IIa trial for Alcohol Use Disorder (AUD).

The trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of the company’s MEAI-based oral candidate. Recent top-line results from the first cohort were described as positive and the Data and Safety Monitoring Board gave a unanimous recommendation to continue, supporting trial momentum across active sites.

Clearmind Medicine (Nasdaq: CMND) announced three clinical milestones for its MEAI-based oral therapy CMND-100 targeting Alcohol Use Disorder: positive top-line safety and preliminary efficacy data from the trial's first cohort of six participants (reported Nov 18, 2025); a unanimous independent DSMB recommendation to continue following an unblinded safety review (Nov 24, 2025); and activation of a new Israeli site, Tel Aviv Sourasky Medical Center, with first patient enrolled (Nov 25, 2025), joining Yale, Johns Hopkins and Hadassah sites. The Phase I/IIa trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy and the new site may accelerate multinational recruitment for subsequent phases.

Clearmind Medicine (Nasdaq: CMND) announced that Tel Aviv Sourasky Medical Center (TASMC) has enrolled the first patient in the company’s FDA-approved multinational Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD) on Nov 25, 2025. TASMC, led by Prof. David Zeltser, is now fully activated and joins sites including Yale, Johns Hopkins, and Hadassah.

The trial is assessing safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a non-hallucinogenic oral MEAI-based compound. Recent top-line data from the first completed cohort reported excellent safety and adherence with no serious adverse events. Management said TASMC enrollment accelerates global recruitment efforts.

Clearmind Medicine (Nasdaq: CMND) announced that its independent Data and Safety Monitoring Board completed an interim review of the FDA‑approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Nov 24, 2025 and unanimously recommended the trial continue.

Key interim findings from the initial dosing cohort included no serious adverse events, general good tolerability, and high adherence to the dosing regimen and study protocol. The multinational trial evaluates safety, tolerability, pharmacokinetics, and preliminary efficacy in reducing alcohol cravings and consumption.